GlassScriptPhysician profile
Anna L Williamson
NPI 1447807805
$3,137.64
in general payments reported to CMS, 2019-2025
33 companies · $740 in 2025
The $740 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $345 · 2022: $411 · 2023: $577 · 2024: $1,064 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,381.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,354.80 | 2021-2025 | |
| Janssen Biotech, INC. | $310.93 | 2022-2025 | Tremfya, Stelara |
| Celgene Corporation | $287.98 | 2023-2024 | Zeposia |
| Amgen INC. | $149.70 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $112.83 | 2021 | |
| Ardelyx, INC. | $84.19 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $74.29 | 2023-2025 | Dupixent |
| Gilead Sciences, INC. | $72.57 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.59 | 2022-2024 | Entyvio |
| Merck Sharp & Dohme LLC | $56.77 | 2022-2023 | Dificid |
| Nestle Healthcare Nutrition INC. | $47.45 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $44.94 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.94 | 2022-2023 | Xifaxan, Trulance |
| Qol Medical, LLC | $41.01 | 2023-2024 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $38.16 | 2024-2025 | Voquezna |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $35.97 | 2024-2025 | Resmetirom, Rezdiffra |
| Celltrion USA INC. | $27.44 | 2025 | Vegzelma |
| Enterra Medical, INC. | $26.10 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.24 | 2022 | |
| Daiichi Sankyo INC. | $20.84 | 2021 | |
| Janssen Pharmaceuticals, INC | $20.11 | 2021 | |
| Aimmune Therapeutics, INC. | $19.87 | 2025 | Zenpep |
| Ucb, INC. | $18.74 | 2021 | |
| Intercept Pharmaceuticals, INC. | $18.17 | 2025 | |
| Pfizer INC. | $16.09 | 2024 | |
| Redhill Biopharma INC. | $16.08 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.69 | 2021 | |
| Braintree Laboratories, INC. | $15.56 | 2024 | Suflave |
| Novo Nordisk INC | $15.52 | 2023 | Saxenda, Wegovy |
| Sobi, INC | $15.45 | 2022 | |
| Lilly USA, LLC | $15.34 | 2025 | Omvoh |
| Janssen Scientific Affairs, LLC | $13.54 | 2024 | |
| Ironwood Pharmaceuticals, INC | $11.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Williamson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.